Review article

Multiple endocrine neoplasia type 2 and *RET*: from neoplasia to neurogenesis

Jordan R Hansford, Lois M Mulligan

Abstract

Multiple endocrine neoplasia type 2 (MEN 2) is an inherited cancer syndrome characterised by medullary thyroid carcinoma (MTC), with or without pheochromocytoma and hyperparathyroidism. MEN 2 is unusual among cancer syndromes as it is caused by activation of a cellular oncogene, *RET*. Germline mutations in the gene encoding the RET receptor tyrosine kinase are found in the vast majority of MEN 2 patients and somatic *RET* mutations are found in a subset of sporadic MTC. Further, there are strong associations of *RET* mutation genotype and disease phenotype in MEN 2 which have led to predictions of tissue specific requirements and sensitivities to RET activity. Our ability to identify genetically, with high accuracy, subjects with MEN 2 has revolutionised our ability to diagnose, predict, and manage this disease. In the past few years, studies of RET and its normal ligand and downstream interactions and the signalling pathways it activates have clarified our understanding of the roles played by RET in normal cell survival, proliferation, and differentiation, as well as in disease. Here, we review the current knowledge of the normal functions of *RET* and the effects of mutations of this gene in tumorigenesis and in normal development.

(J Med Genet 2000;37:817–827)

Keywords: multiple endocrine neoplasia type 2; *RET*; receptor tyrosine kinase

Recognition of cancer as a genetic disease has contributed to the rapid advances of recent years in our ability to identify, diagnose, and treat human neoplasia. Nowhere have the inroads made in these areas been clearer, or had more impact, than in the inherited cancer syndromes, where the presence of multiple, often diverse, disease symptoms and tumour types have made diagnosis and screening highly problematical. The genetic characterisation of many of these diseases in the past few years has provided us with the tools for recognition, screening, and management and has had a huge impact on the perceived burden of these

diseases for families. Elucidation of genetic mechanisms and their functional consequences has also given us clues as to the broader systems disrupted in these syndromes which, in turn, have further implications for normal developmental or survival processes. The inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2) and its causative gene, *RET*, are a useful paradigm for both the impact of genetic characterisation on disease management and also for the much broader developmental implications of these genetic events.

The RET receptor tyrosine kinase

MEN 2 arises as a result of activating mutations of the *RET* (REarranged during Transfection) proto-oncogene.^{1–5} *RET* encodes a receptor tyrosine kinase expressed primarily in neural crest and urogenital precursor cells.^{6–8} It is a developmentally important gene, required for kidney morphogenesis, maturation of peripheral nervous system lineages, and for differentiation of spermatogonia.^{6–9–10} Like other receptor tyrosine kinases, the RET protein comprises extracellular, transmembrane, and cytoplasmic domains (fig 1). The extracellular sequences include regions with homology to the cadherin family of cell adhesion molecules and a large cysteine rich region.^{11–14} Twenty seven of 28 cysteine residues within the cysteine rich domain are conserved between species, suggesting a critical role for these residues in formation of intramolecular disulphide bonds, and thus in determining the tertiary structure of RET proteins.^{11–13} The intracellular tyrosine kinase domain is similar to that of other receptor tyrosine kinases and functions in phosphorylation of key tyrosine residues involved in interaction with downstream targets and activation of signalling pathways.

Under normal conditions, the RET receptor is activated through a multicomponent complex involving members of two distinct groups of proteins: a soluble ligand of the glial cell line derived neurotrophic factor (GDNF) family, and a cell surface bound coreceptor of the GDNF family receptors α (GFR α) protein family (fig 2). The GDNF proteins are members of the TGF- β subfamily¹⁵ and have all been shown to act as potent neuronal

Department of
Pathology, Queen's
University, Kingston,
Ontario K7L 3N6,
Canada

J R Hansford
L M Mulligan

Department of
Paediatrics, Queen's
University, 20 Barrie
Street, Kingston,
Ontario K7L 3N6,
Canada

J R Hansford
L M Mulligan

Correspondence to:
Dr Mulligan,
mulligal@post.queensu.ca

Figure 1 Schematic diagram of the structures of the RET gene and protein. Protein domains are indicated. Positions of MEN 2 mutations are shown relative to the 21 RET coding exons and to their corresponding position in the RET protein. Only mutations found in multiple independent families and/or for which functional significance has been confirmed are shown.

survival factors.¹⁶ Four members of this family have been identified to date, including GDNF, neurturin (NTN), persephin (PSP), and artemin (ART).¹⁶

Although all four GDNF family members act as the ligands for RET, they do not bind RET directly but first interact with a cell surface bound coreceptor of the GFR α family (fig 2). These coreceptors do not have intracellular domains but are anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage.^{17,18} There are four GFR α family members identified to date (GFR α -1-4).¹⁶ GDNF family members form high affinity interactions with a specific member of the GFR α family. GFR α -1 primarily binds GDNF, GFR α -2 binds NTN, GFR α -3 binds ART, and GFR α -4 binds PSP (fig 2).¹⁶ All of the different GDNF/GFR α complexes bind to, and activate, RET. The GDNF and GFR α family members have distinct and overlapping expression patterns,¹⁶ suggesting that activation of RET by formation of ligand receptor complexes is a tightly regulated process. It is thus not surprising that we see significant disease phenotypes associated with aberrant RET activation.

Multiple endocrine neoplasia type 2 (MEN 2)

MEN 2 is an inherited cancer syndrome characterised by medullary thyroid carcinoma (MTC), a tumour of the neural crest derived parafollicular C cells responsible for the production of calcitonin.¹⁹ While MTC, or its precursor lesion C cell hyperplasia, are the most common disease phenotypes in MEN 2 patients (clinically significant disease occurring in 70% of cases), other lesions are also promi-

nent. MEN 2 may be classified into three subtypes based on their occurrence. MTC, pheochromocytoma (PC), and hyperparathyroidism (HPT) characterise MEN 2A, the most common of these subtypes. PC, a tumour of the adrenal chromaffin cells, occurs in approximately 50% of MEN 2A patients, while only 15-30% of cases develop HPT or parathyroid adenomas.²⁰⁻²² PC is also present in approximately 50% of those with the MEN 2B subtype. Parathyroid involvement is rare in these cases, and characteristic developmental abnormalities including marfanoid habitus, thickened corneal nerves, and ganglioneuromatosis of the buccal membranes and the gastrointestinal tract are prevalent.^{19,23,24} MEN 2B is considered to be the most aggressive of the MEN 2 subtypes, with a median age of onset 10 years earlier than seen in MEN 2A.^{19,24}

The third subtype of MEN 2, familial MTC (FMTc), is characterised by the presence of MTC in multiple family members (four or more) as its only disease phenotype.²⁵ Families with a smaller number of MTC cases but without other phenotypes are more difficult to classify as they may represent small FMTc families or MEN 2A families in which PC or HPT have not yet manifested. FMTc is generally considered the least aggressive of the three MEN 2 subtypes with a later onset than MEN 2A or 2B.²⁵

Genetics of MEN 2

MEN 2 is inherited in an autosomal dominant fashion with variable, age dependent penetrance.²⁶ Unlike other cancer syndromes, which are associated with inactivation of tumour suppressor genes, each of the MEN 2 subtypes arises as a result of activating

Figure 2 (A) Schematic diagram showing the members of the RET multimeric signalling complexes and the primary interactions of the different GDNF family ligands and GFRα family members. (B) Predicted model of RET activation by its ligand and coreceptor molecules.¹⁸ Soluble ligands bind cell surface bound GFRα family members which, in turn, present the ligands to RET, mediating its dimerisation and autophosphorylation.

mutations of the *RET* proto-oncogene. Missense mutations affecting cysteine residues in the RET extracellular domain are found in patients with MEN 2A (fig 1, table 1). Single base pair substitutions in one of five codons, 609, 611, 618, 620 (exon 10) or 634 (exon 11), are found in >98% of MEN 2A families.^{3 27 28} (fig 1, tables 1 and 2). In each case, these changes result in replacement of a critical cysteine residue by any of several amino acids (table 1). Approximately 87% of MEN 2A mutations affect codon 634 (table 2) and the most frequent substitution at this codon is a cysteine to arginine change (C634R), found in more than 50% of cases.^{27 28} Rarely, duplication/insertion mutations in exon 11 have been observed in MEN 2A (fig 1), resulting in the insertion of three or four amino acids, including a cysteine residue, within the cysteine rich domain (table 1).^{29 30} As a result of

each of the above mutations, a cysteine residue normally involved in the intramolecular disulphide bonds that determine the tertiary structure of RET is unpaired and can form intermolecular bonds with other RET molecules.^{31–33} The outcome is dimerisation and constitutive activation of the RET tyrosine kinase.^{31 33}

Many of the same mutations responsible for MEN 2A have also been found in FMTC (table 1, fig 1). Substitutions of cysteine codons 609, 611, 618, 620, and 634 in exons 10 and 11 are found in more than 80% of FMTC families (table 2).^{27 28} However, unlike MEN 2A, FMTC mutations are relatively evenly distributed among codons 618, 620, and 634 (table 2).^{27 28} Less frequently, mutations of cysteine codon 630 and insertions including cysteine residues elsewhere in the cysteine rich region have been identified in FMTC (fig 1).^{34 35}

Table 1 *RET mutations and their associated phenotypes**

Exon	Codon No	Base pair change	Amino acid change	Phenotype
10	609	TGC to CGC	Cys to Arg	MEN 2A, FMTC
		TGC to TAC	Cys to Tyr	MEN 2A
	611	TGC to TAC	Cys to Tyr	MEN 2A
		TGC to TGG	Cys to Trp	MEN 2A, FMTC
	618	TGC to GGC	Cys to Gly	FMTC
		TGC to TTC	Cys to Phe	MEN 2A
		TGC to TCC	Cys to Ser	MEN 2A, FMTC
		TGC to AGC	Cys to Ser	MEN 2A, FMTC
		TGC to GGC	Cys to Gly	MEN 2A
		TGC to CGC	Cys to Arg	MEN 2A, FMTC
		TGC to TAC	Cys to Tyr	MEN 2A, FMTC
		TGC to TGA	Cys to Stop	MEN 2A
		TGC to CGC	Cys to Arg	MEN 2A, FMTC
		TGC to TAC	Cys to Tyr	MEN 2A
	620	TGC to TTC	Cys to Phe	MEN 2A
		TGC to TCC	Cys to Ser	MEN 2A
		TGC to GGC	Cys to Gly	MEN 2A
		TGC to TTC	Cys to Phe	FMTC
		TGC to TAC	Cys to Tyr	MEN 2A, FMTC
		TGC to CGC	Cys to Arg	MEN 2A
		TGC to TTC	Cys to Phe	MEN 2A, FMTC
		TGC to GGC	Cys to Gly	MEN 2A
		TGC to TGG	Cys to Trp	MEN 2A
		TGC to AGC	Cys to Ser	MEN 2A
11	630	TGC to TTC	Cys to Phe	FMTC
		TGC to TAC	Cys to Tyr	MEN 2A, FMTC
	634	TGC to CGC	Cys to Arg	MEN 2A
		TGC to TTC	Cys to Phe	MEN 2A, FMTC
		TGC to GGC	Cys to Gly	MEN 2A
		TGC to TGG	Cys to Trp	MEN 2A
		TGC to AGC	Cys to Ser	MEN 2A
		TGC to TCC	Cys to Ser	MEN 2A, FMTC
		GAG to GAC	Glu to Asp	FMTC
		TTG to TTT	Leu to Phe	MEN 2A, FMTC
		TTG to TTC	Leu to Phe	MEN 2A, FMTC
	791	TAT to TTT	Tyr to Phe	FMTC
14	804	GTG to TTG	Val to Leu	FMTC
		GTG to ATG	Val to Met	
	804 & 806	804- GTG to ATG	Val to Met	MEN 2B
		806- TAC to TGC	Tyr to Cys	
15	883	GCT to TTT	Ala to Phe	MEN 2B
	891	TCG to GCG	Ser to Ala	FMTC
16	918	ATG to ACG	Met to Thr	MEN 2B
Duplications	Base pair No	Inserted sequence	Amino acids inserted	Phenotype
8	1741–1742	ins GAG GAG TGT	EEC 531–532	FMTC
11	2056–2057	ins TCG CGC ACG	CRT 636–637	MEN 2A
	2049–2050	ins ACG AGC TGT GCC	CRT 634–635	MEN 2A

*Only mutations found in multiple independent families and/or for which functional significance has been confirmed are shown.

Interestingly, the C634R mutation most common in MEN 2A is not found in FMTC families.^{27,28} In addition to mutations of extracellular cysteines, FMTC is also associated with amino acid substitutions in the intracellular tyrosine kinase domain. Mutations have been reported in exon 13 (E768D),^{36–39} exon 14 (V804L or V804M),^{36,40,41} and exon 15 (S891A).^{42,43} Additional mutations of codons 790, 791, or 844 have been identified in a German patient population but the general distri-

Table 2 *Distribution of RET mutations in MEN 2*

Codon No	Phenotype	Frequency*
609	MEN 2A	<0.01
	FMTC	0.04
611	MEN 2A	0.02
	FMTC	<0.01
618	MEN 2A	0.03
	FMTC	0.30
620	MEN 2A	0.06
	FMTC	0.21
630	FMTC	<0.01
	MEN 2A	0.87
634	FMTC	0.26
	FMTC	0.08
768	FMTC	<0.01
790	FMTC	<0.01
791	FMTC	<0.01
804	FMTC	0.03
883	MEN 2B	0.05
891	FMTC	<0.01
918	MEN 2B	0.94

*Only mutations found in multiple independent families are included.

bution of these mutations has not yet been determined.³⁹ The mechanisms by which each of these intracellular mutations activates RET has not been functionally demonstrated; however, they are predicted to alter either ATP or RET substrate binding.^{36,38,43–45}

MEN 2B is associated primarily with a single missense mutation of codon 918 (M918T) which is found in more than 90% of all reported cases (table 2).^{4,5,27,28,46} Mutations of codon 883 in exon 15 (A883F) have also been shown to occur in a small number of MEN 2B cases.^{47,48} These variants are exclusively associated with the MEN 2B phenotype. Amino acids 883 and 918 both lie within the substrate binding pocket of the RET tyrosine kinase⁴⁹ and mutations of these codons result in RET proteins with altered substrate specificity. These altered RET isoforms seem to recognise and phosphorylate substrates preferred by cytoplasmic tyrosine kinases such as c-src and c-abl, rather than the normal substrates of receptor tyrosine kinases.^{49–51} Recently, MEN 2B associated with a double germline mutation, V804M and Y806C, has been reported.⁵² This combination of variants has been shown in vitro to be significantly more transforming than either variant alone and this mutant is predicted to have similar biological properties to the other MEN 2B-RET isoforms.⁵³ This double mutation has suggested that multiple low penetrance variants in *RET* can contribute to a more aggressive disease phenotype.⁵³

Genotype and phenotype

As can be seen from the descriptions above and in table 1, there are strong correlations of MEN 2 disease phenotype and specific *RET* sequence changes. Mutations affecting cysteine residues in the extracellular cysteine rich domain of RET have been identified in both FMTC and MEN 2A. However, while MEN 2A is associated most frequently with mutations of codon 634, and particularly with the C634R change, mutations in FMTC are more evenly distributed and the C634R mutation is notably absent.^{27,28} The association of *RET* mutations with disease phenotype is even clearer if we consider the occurrence of component tumour types, rather than disease subtypes. Several studies have shown a strong correlation between the presence of a codon 634 mutation and the occurrence of PC and/or HPT in MEN 2 families.^{3,27,28,54} A further association of the specific C634R mutation with HPT, reported in one large study,³ has been more difficult to confirm on a family as unit basis.^{21,54} Comparisons between studies have been confounded by differences in screening protocols among studies and, potentially, by patient age and follow up, since HPT is strongly correlated with patient age.²¹ However, an increased risk of HPT on a person as unit basis in families with C634R mutations has been reported, suggesting that this mutation does confer risk for HPT.²¹

The genotype/phenotype associations in MEN 2 reflect differences in behaviour and function among the mutant RET isoforms. Protein localisation analyses have shown that

RET isoforms with mutations of codons 609, 618, and 620 are not as efficiently translocated to the cell surface as wild type or other mutant RET isoforms.⁵⁵⁻⁵⁸ As described above, these mutations are also associated with lower risks for PC and HPT. Together, these data suggest a model in which there are tissue specific differences in sensitivity to RET activation, with thyroid being most sensitive and parathyroid least sensitive.^{3 58} According to this prediction, all RET mutations are sufficient to promote tumorigenesis in the thyroid and, consequently, MTC is associated with all MEN 2 subtypes. The adrenal and parathyroid glands are less sensitive to RET activation and, thus, PC and HPT are primarily associated with the most penetrant of RET mutations affecting cysteine 634, where the maximal amounts of mutant RET protein are found on the cell surface.^{3 58}

To date, RET mutations of codons 768, 804, and 891 have been associated primarily with the FMTC phenotype. The risk of other tumour phenotypes is low in subjects with these mutations.^{27 28 41} The absence of HPT and PC in families with 768, 804, and 891 mutations is consistent with in vitro studies suggesting that RET proteins with these variants have a lower transforming efficiency than isoforms with codon 634 or 918 mutations.^{44 45} Recent studies have also predicted that V804M mutations particularly may be associated with a later onset and less aggressive disease course.^{41 59} Together, these data suggest that mutations of RET exons 13, 14, and 15 may represent lower penetrance mutations with a less aggressive associated phenotype, although further families will need to be accrued before this association can be applied clinically.

RET mutations in sporadic tumours

In addition to its role in familial disease, RET mutations have also been implicated in sporadic tumours of MEN 2 type. The majority of MTC cases (>75%) have no associated family history or other indications that might suggest a hereditary cause.¹⁹ However, several large population studies have shown that 3-7% of these cases represent occult or de novo MEN 2 cases with germline RET mutations.^{21 60 61} Approximately 23 to 70% of true sporadic MTC have been shown to harbour somatically occurring RET mutations.⁶² Analyses of subpopulations of tumour cells or multiple metastases from a single patient have shown that RET mutations are apparent in subsets of clones, suggesting that RET mutations are not initiating but progression events in sporadic MTC.^{63 64} The vast majority of these are the M918T mutation associated with the MEN 2B phenotype, although other mutations of the cysteine rich region and exons 13-15 have been reported. Interestingly, a rare polymorphic sequence variant (c.2439C>T; S836S) was recently shown to be over-represented in patients with sporadic MTC and M918T mutations.⁶⁵ The significance of this genotype/phenotype association remains to be determined.

Somatic RET mutations are less frequent in PC (10-15% cases),⁶² perhaps reflecting the lower sensitivity of adrenal chromaffin cells to RET activation.^{3 58} The M918T mutation is also common here (50%); however, other mutations such as missense mutations of exons 10 and 11 and deletions in the cysteine rich region have been reported.⁶²

RET mutations have not been detected in sporadic HPT or parathyroid adenoma.⁶² Further, studies of other tumour types including small cell lung carcinoma, neuroblastoma, malignant melanoma, and others have also failed to identify RET mutations, suggesting that activation of the RET receptor in other cell types may not have significant neoplastic implications.⁶⁶⁻⁶⁸

RET downstream signalling

RET's functions in normal and tumorigenic cells are mediated by a complex series of downstream interactions. RET can trigger growth, differentiation, or survival responses, depending on the cell type or developmental stage in which it is activated. Dimerisation of RET receptors, either owing to the presence of activating mutations or ligand binding, results in autophosphorylation of intracellular tyrosine residues. To date, nine of RET's 18 intracellular tyrosines have been shown to be phosphorylated upon RET activation.^{11 69} Adaptor proteins containing SH2 domains recognise the amino acid sequences surrounding these phosphorylated residues and target these sites specifically. Interactions identified to date include GRB7 and 10, binding at tyrosine 905 (Y905), phospholipase C- γ (PLC- γ) at Y1015, SHC at Y1062, and GRB2 at Y1096 (fig 3).^{31 70-76} RET also interacts with enigma, a cytoplasmic, membrane anchored LIM domain protein which binds RET Y1062 in a phosphorylation independent manner and may play a role in positioning the RET tyrosine kinase with respect to the cell membrane.⁷⁶

RET activates a number of well characterised downstream signalling pathways through interactions with these adaptor proteins (fig 3). RET has been shown to stimulate RAS mediated activation of the MAP kinase pathway which is required for both neuronal survival and differentiation.⁷⁷⁻⁸¹ The RAS-MAP kinase cascade is activated through SHC and GRB2 (Y1062) or directly through GRB2 binding (Y1096). GRB7 or 10 binding (Y905) has also been linked to activation of this pathway.⁸² In some cell types, RET mediated activation of RAS dependent pathways can result in cellular differentiation,⁸¹ while in other cell types, RET activation may actually block RAS induced differentiation by preventing nuclear translocation of ERK and induction of immediate early gene transcription.⁸³

Activation of phospho-inositol 3 (PI3) kinase, probably through RET's interaction with GRB2 and GAB1 and recruitment of the PI3 kinase regulatory subunit, has also been implicated in cell proliferation and survival.^{51 84} RET stimulation of this pathway is further associated with cell motility and cellular interactions and can lead to lamellipodia formation and

Figure 3 Schematic diagram showing some of the downstream pathways activated by RET. Specific downstream interactions confirmed *in vitro* are indicated. Dotted lines indicate predicted signalling paths not yet confirmed in this system.

phosphorylation of proteins linked to formation of focal adhesions (for example, paxillin, focal adhesion kinase (FAK), Crk associated substrate p130cas) and to increased expression of the gap junctional protein connexin 43 (fig 3).^{50 80 85-89} RET also acts through PI3 kinase to stimulate protein kinase B/AKT activation which plays a role in cell survival and proliferation but also contributes to RET's oncogenic potential.^{51 84 88} RET has also been shown to activate the c-jun N-terminal kinase (JNK) pathway through a cdc42/RAC1 small GTPase which contributes to establishment of the neoplastic phenotype.⁹⁰ It is not yet clear how this is triggered by RET, but JNKs have been shown to lie downstream of PI3 kinase in other systems.

Finally, RET has been shown to interact with PLC- γ through Y1015. This association is also required for full oncogenic activation of RET.^{71 91}

As *MEN2A* and *2B-RET* mutations contribute to RET activation via different mechanisms, it is perhaps not surprising that different tyrosine residues appear to be significant to transformation in each case. Phosphorylation of tyrosines 864 and 952 is crucial to transformation associated with the MEN 2B mutation of codon 918, while Y905 phosphorylation is essential to transformation in the context of MEN 2A mutations.^{69 82} Other tyrosines, such

as Y1015, Y1062, and Y1096, are phosphorylated in all mutation contexts and are universally required for transformation,^{73 92-94} although the extent of activity may vary. For example, in response to MEN 2B type RET mutations, Y1096 has relatively reduced phosphorylation while RET stimulation of PI3 kinase is relatively increased, as compared to *MEN2A* mutations.^{50 51 69 90}

The downstream interactions of RET are further complicated by alternative splicing of 3' exons which results in three protein isoforms with nine (RET9), 51 (RET51), or 43 (RET43) unique C-terminal amino acids (figs 1 and 3).^{11 95 96} These isoforms differ in their relative binding of adaptor proteins to Y1062 which lies in three distinct amino acid contexts in these proteins.^{75 97 98} Further, Y1096, discussed above, is present in only the RET51 protein isoform. Consistent with these differences, RET isoforms have different efficiencies in inducing transformation or differentiation *in vitro* and distinct developmental expression patterns *in vivo*.^{75 97-99}

Diagnosis and management of MEN 2

Recognition of the genetic events responsible for MEN 2 have significantly improved our ability to diagnose and manage the disease. The prognosis for MEN 2 patients is very good with early diagnosis and intervention. Previously,

repeated biochemical testing of at risk subjects was required to identify those manifesting MEN 2 symptoms. Blood pressure monitoring and quantitation of 24 hour urine catecholamines were used to identify adrenal hyperplasia or PC.¹⁰⁰ A provocation assay for increased calcitonin or calcium release (indicative of C cell hyperplasia) was used to screen subjects at risk for MTC.¹⁰⁰ A raised test result indicated the presence of C cell hyperplasia or MTC which would be managed surgically. Unfortunately, these tests were subject to false positive results and were notoriously inaccurate in young children, where testing was most critical.^{101 102} However, the major disadvantage of these tests was that they did not distinguish the family member who had not inherited a *MEN2* mutation, and was therefore not at risk of the disease, from presently asymptomatic subjects who would in future develop the disease phenotype.

Currently, early genetic screening for *RET* mutations is considered the standard of care for MEN 2.^{100 103} The advent of genetic testing methods has made it possible to detect those people who have inherited a *MEN2-RET* mutation before the onset of disease symptoms and the associated morbidity or mortality. Predictive and diagnostic testing is facilitated by the high incidence of detectable mutations (>95%) and the small number of target codons.^{27 28} If a member of a family with a known *MEN2-RET* mutation is found not to have that mutation, they are not considered at risk of MEN 2 and should not require further screening. In the case of subjects where the *MEN2-RET* mutation is found, prophylactic thyroidectomy is recommended before the age of 6 years,¹⁰³ since MTC has been diagnosed at very early ages in MEN 2 families.¹⁰⁴ In cases of MEN 2B, which is associated with an earlier age of onset and more aggressive disease than other MEN 2 subtypes, surgery before the age of 3 may be warranted.^{100 101 103 104}

Although current genetic tests can identify the vast majority (>98%) of MEN 2 cases,^{27 28} there remain a few families for which a *RET* mutation has not been identified and subjects for whom it has not been possible to exclude a familial origin for MTC. In these cases, family members must be treated as in the pre-DNA testing era with frequent biochemical screening of at risk subjects.

Other *RET* related phenotypes

In addition to MEN 2, *RET* has been implicated in several other pathologies including papillary thyroid carcinoma and Hirschsprung disease.

PAPILLARY THYROID CARCINOMA

Papillary thyroid carcinoma (PTC) is a tumour of the thyroid follicular cells which is associated with frequent somatically occurring rearrangements of the *RET* gene.^{105 106} As a result of either chromosomal translocation or inversion, the 3' portion of the *RET* gene encoding the intracellular domains becomes juxtaposed to 5' sequences from one of several other genes (*H4*, *Rla*, *ELE1*, *HTIF1*, *GOLGA5*, *RFG7*). Al-

though these partner genes have diverse normal functions, each appears to contribute a domain with dimerisation potential to the *RET* fusion protein.^{105 106} The resultant chimeric molecule can dimerise and autophosphorylate constitutively to activate downstream signalling in a cell type in which *RET* is not normally expressed, leading to cellular transformation. Recent studies have shown that the incidence of *RET* mutations in PTC is significantly higher in people who have suffered radiation exposure, as in the Chernobyl region.¹⁰⁶ Initially, rearrangements juxtaposing the *ELE1* and *RET* genes are the most common in those subjected to higher radiation doses, suggesting that this chimeric protein may contribute to rapid tumour formation.¹⁰⁶ However, at longer intervals after exposure, the frequency of *RET* rearrangements has declined and a shift towards *H4/RET* chimeras has been noted.¹⁰⁶

HIRSCHSPRUNG DISEASE

Hirschsprung disease (HSCR) is a developmental disorder marked by the lack of innervation of variable lengths of the hind gut.¹⁰⁷ HSCR affects approximately 1/5000 neonates and may occur in either sporadic or heritable forms.¹⁰⁷ Inactivating mutations of *RET*, including deletions, insertions, and point mutations, have been detected in a subset of HSCR patients.^{62 108} The outcome of these changes is to reduce the amount of functional *RET* protein on the cell surface, resulting in haploinsufficiency for *RET*.^{45 55 56 109 110} Germ-line *RET* mutations are found in approximately 40% of familial HSCR cases and in 3-7% of sporadic HSCR cases.^{111 112} Several studies have also identified mutations of the *RET* ligands *GDNF* and *NTN* in patients with HSCR,¹¹³⁻¹¹⁶ although mutations of the *GFRα* family are surprisingly absent.¹¹⁷⁻¹¹⁹ These mutations are thought to act primarily as modifiers of the *RET* mutation phenotype in HSCR. Recent studies have also shown an association between the HSCR phenotype and polymorphisms in exons 2, 13, and 15 of *RET* in sporadic HSCR, even in the absence of *RET* mutations, suggesting that the level of *RET* function, even within the normal range, has implications for expression of the HSCR phenotype.^{120 121} The co-occurrence of mutations or variants of *RET*, mutations at other loci such as the endothelin B receptor gene,^{122 123} and an association with an as yet unknown locus on chromosome 9q31¹²⁴ support a multi-genetic origin for HSCR in which *RET* is only one of the players, albeit a significant one.

In rare families, HSCR and MEN 2A or FMTC may co-occur, because of the same *RET* mutation.^{108 125 126} These phenotypes are generally associated with cysteine to arginine changes in exon 10 of *RET*. As described above, protein isoforms containing these specific mutations have been shown to translocate to the cell surface with low efficiency.^{55 57 58} As a result, insufficient *RET* protein is available in the developing enteric nervous system and HSCR can result, while at the same time activation of the *RET* signalling pathways in the

thyroid/adrenal glands is sufficient to permit hyperplasia or tumour formation.

RET and other pathologies: from cause to cure?

To date, RET has not been implicated in other disease pathologies, but it remains of interest as a target of therapies in patients with neurodegenerative disease or nerve injuries. The GDNF family of RET ligands are well known for their neuroprotective properties, especially in dopaminergic neurones.¹⁶ In particular, activation of RET by GDNF ligands promotes survival of dopaminergic neurones and has thus been of interest as a target for therapies in diseases such as Parkinson's disease.¹²⁷⁻¹²⁹ A variety of studies have also shown that signalling through RET is increased in response to a range of insults and may represent an important survival factor for neurones exposed to physical or chemical insult. The clinical implications of these findings have yet to be explored.

Recent studies have shown that RET is required for normal development of spermatogonia and, hence, normal sperm formation¹⁰ and a potential role for RET in therapies for male infertility has been proposed.

Conclusion

It has been less than 10 years since the relationship between RET mutations and MEN 2 was first described. In that time, we have revolutionised the management and prognosis for this disease in ways rarely possible for human cancers. The study of RET, and its role in normal development, have since then expanded in new directions and identified other disease associations and yet our knowledge of the system is still very preliminary. In the next few years we can predict that our understanding of RET will turn towards its normal functions and how we may use these in treatment or mitigation of diseases for which we are only beginning to predict a role for RET.

- 1 Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. *Hum Mol Genet* 1993;2:851-6.
- 2 Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* 1993;363:458-60.
- 3 Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, Thibodeau SN, Ponder BAJ. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. *Nat Genet* 1994;6:70-4.
- 4 Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson CE, Tunnacliffe A, Ponder BAJ. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. *Hum Mol Genet* 1994;3:237-41.
- 5 Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppner JWM, Ploos van Amstel HK, Romeo G, Lips CJM, Buys CHCM. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. *Nature* 1994;367:375-6.
- 6 Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. *Nature* 1994;367:380-3.
- 7 Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. *Development* 1993;119:1005-17.

- 8 Avantiagato V, Dathan NA, Grieco M, Fabien N, Lazzaro D, Fusco A, Simeone A, Santoro M. Developmental expression of the RET protooncogene. *Cell Growth Diff* 1994;5:305-11.
- 9 Durbec PL, Larsson-Blomberg LB, Schuchardt A, Costantini F, Pachnis V. Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts. *Development* 1996;122:349-58.
- 10 Meng X, Lindahl M, Hyvonen ME, Parvinen M, de Rooij DG, Hess MW, Raatikainen-Ahokas A, Sainio K, Rauvala H, Lakso M, Pichel JG, Westphal H, Saarma M, Sariola H. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. *Science* 2000;287:1489-93.
- 11 Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. *Oncogene* 1998;3:571-8.
- 12 Schneider R. The human protooncogene ret: a communicative cadherin? *Trends Biol Sci* 1992;17:468-9.
- 13 Iwamoto T, Taniguchi M, Asai N, Ohkusu K, Nakashima I, Takahashi M. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. *Oncogene* 1993;8:1087-91.
- 14 Takahashi M, Buma Y, Hiai H. Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. *Oncogene* 1989;4:805-6.
- 15 Lin LFH, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* 1993;260:1130-2.
- 16 Baloh RH, Enomoto H, Johnson EM Jr, Milbrandt J. The GDNF family ligands and receptors - implications for neural development. *Curr Opin Neurobiol* 2000;10:103-10.
- 17 Treanor JJS, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A. Characterization of a multicomponent receptor for GDNF. *Nature* 1996;382:80-3.
- 18 Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock BW, Fox GM. GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR- α , a novel receptor for GDNF. *Cell* 1996;85:1113-24.
- 19 Schimke RN. Genetic aspects of multiple endocrine neoplasia. *Annu Rev Med* 1984;35:25-31.
- 20 Howe JR, Norton JA, Wells SA. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. *Surgery* 1993;114:1070-7.
- 21 Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C, Modigliani E, Rohmer V, Schlumberger M, Eng C, Guillausseau PJ, Lenoir GM. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs a Calcitonine. *J Clin Endocrinol Metab* 1998;83:487-91.
- 22 Gagel RF. Pheochromocytoma, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. *N Engl J Med* 1994;330:1090-1.
- 23 Gorlin RJ, Sedano HO, Vickers RA, Cervinka J. Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid - a syndrome. *Cancer* 1968;22:293-9.
- 24 Carney JA, Go VL, Sizemore GW, Hayles AB. Alimentary-tract ganglioneuromatosis. A major component of the syndrome of multiple endocrine neoplasia, type 2b. *N Engl J Med* 1976;95:1287-91.
- 25 Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, Wells SA. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. *Br J Surg* 1986;73:278-81.
- 26 Easton DF, Ponder MA, Cummings T, Gagel RF, Hansen HH, Reichlin S, Tashjian AH, Telenius-Berg M, Ponder BAJ. Cancer Research Campaign Medullary Thyroid Group. The clinical and screening age-at-onset distribution for the MEN-2 syndrome. *Am J Hum Genet* 1989;44:208-15.
- 27 Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, Gagel RF, Takai SI, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C. International RET Mutation Consortium. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. *J Intern Med* 1995;238:343-6.
- 28 Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Ploos van Amstel HK, Lips CJM, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xu F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy G, Gharib H, Thibodeau S, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium. *JAMA* 1996;276:1575-9.
- 29 Höppner W, Ritter MM. A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. *Hum Mol Genet* 1997;6:587-90.
- 30 Höppner W, Dralle H, Brabant G. Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A. *Hum Mutat* 1998;suppl 1:S128-30.

- 31 Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the *ret* proto-oncogene by multiple endocrine neoplasia 2A mutations. *Mol Cell Biol* 1995;15:1613-19.
- 32 Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L, Boccardi R, Mondellini P, Scopsi L, Romeo G, Ponder BAJ, Pierotti MA. *RET* activation by germline *MEN2A* and *MEN2B* mutations. *Oncogene* 1995;11:2419-27.
- 33 Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP. Activation of *RET* as a dominant transforming gene by germline mutations of *MEN2A* and *MEN2B*. *Science* 1995;267:381-3.
- 34 Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, Heitz PU. Analysis of the *RET* protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. *Cancer* 1995;76:479-89.
- 35 Pigny P, Bauders C, Wemeau JL, Houcke ML, Crepin M, Caron P, Giraud S, Calender A, Buisine MP, Kerckaert JP, Porchet N. A novel 9-base pair duplication in *RET* exon 8 in familial medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1999;84:1700-4.
- 36 Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, Tourniaire J, Lenoir GM, Romeo G. *RET* mutations in exons 13 and 14 of FMTC patients. *Oncogene* 1995;10:2415-19.
- 37 Boccia LM, Green JS, Joyce C, Eng C, Taylor SAM, Mulligan LM. Mutation of *RET* codon 768 is associated with the FMTC phenotype. *Clin Genet* 1997;51:81-5.
- 38 Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield M, Ponder BAJ. A novel point mutation in the tyrosine kinase domain of the *RET* proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. *Oncogene* 1995;10:509-13.
- 39 Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grusendorf M, Raue F, Ritter MM, Höppner W. A new hot spot for mutations in the *ret* protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. *J Clin Endocrinol Metab* 1998;83:770-4.
- 40 Fattoruso O, Quadro L, Libroia A, Verga U, Lupoli G, Cascone E, Colantuoni V. A GTG to ATG novel point mutation at codon 804 in exon 14 of the *RET* proto-oncogene in two families affected by familial medullary thyroid carcinoma. *Hum Mutat* 1998;suppl 1:S167-71.
- 41 Fink M, Weinhusel A, Niederle B, Haas OA. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the *RET* proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)". *Int J Cancer* 1996;69:312-16.
- 42 Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH. (1997) A novel point mutation in the intracellular domain of the *ret* protooncogene in a family with medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1997;82:4176-8.
- 43 Dang GT, Cote GJ, Schultz PN, Khorana S, Decker RA, Gagel RF. A codon 891 exon 15 *RET* proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy. *Mol Cell Probes* 1999;13:77-9.
- 44 Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajita H, Takahashi M. Biological and biochemical properties of *Ret* with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. *Oncogene* 1999;18:3919-22.
- 45 Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M. Oncogenic activation by two distinct FMTC mutations affecting the tyrosine kinase domain. *Oncogene* 1997;15:393-402.
- 46 Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Goodfellow PJ, Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the *ret* proto-oncogene is associated with multiple endocrine neoplasia type 2B. *Proc Natl Acad Sci USA* 1994;91:1579-83.
- 47 Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PLM, Mulligan LM, Zajac JD, Robinson BG, Eng C. Germline dinucleotide mutation in codon 883 of the *RET* proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. *J Clin Endocrinol Metab* 1997;82:3902-4.
- 48 Smith DP, Houghton C, Ponder BAJ. Germline mutation of *RET* codon 883 in two cases of *de novo* MEN 2B. *Oncogene* 1997;15:1213-17.
- 49 Songyang Z, Carraway KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, Ponder BAJ, Mayer BJ, Cantley LC. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. *Nature* 1995;373:536-9.
- 50 Boccardi R, Mograbi B, Pasini B, Borrello MG, Pierotti MA, Bourget I, Fischer S, Romeo G, Rossi B. The multiple endocrine neoplasia type 2B mutation switches the specificity of the *Ret* tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. *Oncogene* 1997;15:2257-65.
- 51 Murakami H, Iwashita T, Asai N, Shimono Y, Iwata Y, Kawai K, Takahashi M. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by *ret* with the MEN 2B mutation. *Biochem Biophys Res Commun* 1999;262:68-75.
- 52 Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K, Yamaguchi K. Two germline missense mutations at codons 804 and 806 of the *RET* proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. *Jpn J Cancer Res* 1999;90:1-5.
- 53 Iwashita T, Murakami H, Kurokawa K, Kawai K, Miyauchi A, Futami H, Qiao S, Ichihara M, Takahashi M. A two-hit model for development of multiple endocrine neoplasia type 2B by *RET* mutations. *Biochem Biophys Res Commun* 2000;268:804-8.
- 54 Frank-Raue K, Höppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, Deckert HF, Ritter MM, Hampel R, Klempa J, Scholz GH, Raue F, GMTCS Group. Mutations of the *RET* proto-oncogene in German MEN families: relation between genotype and phenotype. *J Clin Endocrinol Metab* 1996;81:1780-3.
- 55 Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M. Biological properties of *Ret* with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. *Cancer Res* 1997;57:2870-2.
- 56 Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Francis V, Billaud M, Fusco A, Santoro M. The different *RET*-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. *Cancer Res* 1997;57:391-5.
- 57 Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T, Lenoir GM, Santoro M, Billaud M. Dual effect on the *RET* receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. *Oncogene* 1998;17:2851-61.
- 58 Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M. Co-segregation of *MEN2* and Hirschsprung's disease: the same mutation of *RET* with both gain and loss-of-function? *Hum Mutat* 1999;13:331-6.
- 59 Shannon KE, Gimm O, Hinze R, Dralle H and Eng C. Germline V804M mutation in the *RET* proto-oncogene in two apparently sporadic cases of MTC presenting in the seventh decade of life. *J Endocr Genet* 1999;1:39-46.
- 60 Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HPH, Ponder MA, Ponder BAJ. Low frequency of germline mutations in the *RET* proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. *Clin Endocrinol* 1995;43:123-7.
- 61 Wohlk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF. Relevance of *RET* proto-oncogene mutations in sporadic medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1996;81:3740-5.
- 62 Eng C, Mulligan LM. Mutations of the *RET* proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours and Hirschsprung disease. *Hum Mutat* 1997;9:97-109.
- 63 Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BAJ. Heterogeneous mutation of the *RET* proto-oncogene in subpopulations of medullary thyroid carcinoma. *Cancer Res* 1996;56:2167-70.
- 64 Eng C, Thomas G, Mulligan L, Healey C, C CH, Frilling A, Raue F, Williams E, Ponder B. Mutation of the *RET* proto-oncogene is correlated with *RET* immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1998;88:4310-13.
- 65 Gimm O, Neuberg DS, Marsh DJ, Dahia PL, Hoang-Vu C, Raue F, Hinze R, Dralle H, Eng C. Over-representation of a germline *RET* sequence variant in patients with sporadic medullary thyroid carcinoma and somatic *RET* codon 918 mutation. *Oncogene* 1999;18:1369-73.
- 66 Hofstra RMW, Cheng NC, Hansen C, Stulp RP, Stelwagen T, Clausen N, Tommerup N, Caron H, Westerveld A, Versteeg R, Buys CHCM. No mutations found by *RET* mutation scanning in sporadic and hereditary neuroblastoma. *Hum Genet* 1996;97:362-4.
- 67 Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WK, Heitz PU. *RET* proto-oncogene point mutations in sporadic neuroendocrine tumors. *J Clin Endocrinol Metab* 1996;81:2041-6.
- 68 Mulligan LM, Timmer T, Ivanchuk SM, Campling BG, Young LC, Rabbitts PH, Sundaresan V, Hofstra RMW, Eng C. Investigation of the genes for *RET* and its ligand complex GDNF/GFR α -1 in small cell lung carcinoma. *Genes Chrom Cancer* 1998;21:326-32.
- 69 Liu X, Vega QC, Decker RA, Pandey A, Worby CA, Dixon JE. Oncogenic *RET* receptors display different autophosphorylation sites and substrate binding specificities. *J Biol Chem* 1996;271:5309-12.
- 70 Pandey A, Duan H, Di Fiore PP, Dixit VM. The *Ret* receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10. *J Biol Chem* 1995;270:21461-3.
- 71 Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P, Radice MT, Pierotti MA. The full oncogenic activity of *Ret/ptc2* depends on tyrosine 539, a docking site for phospholipase C γ . *Mol Cell Biol* 1996;16:2151-63.
- 72 Borrello MG, Pelicci G, Arighi E, DeFilippis L, Greco A, Bongarzone I, Rizzetti MG, Pelicci PG, Pierotti MA. The oncogenic versions of the *ret* and *trk* tyrosine kinases bind Shc and Grb2 adaptor proteins. *Oncogene* 1994;9:1661-8.

- 73 Arighi E, Alberti L, Torriti F, Ghizzoni S, Rizzetti MG, Pelicci G, Pasini B, Bongarzone I, Piutti C, Pierotti MA, Borrello MG. Identification of Shc docking site on Ret tyrosine kinase. *Oncogene* 1997;14:773-82.
- 74 Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG, Pierotti MA. Grb2 binding to the different isoforms of Ret tyrosine kinase. *Oncogene* 1998;17:1079-87.
- 75 Lorenzo MJ, Gish GD, Houghton C, Stonehouse TJ, Pawson T, Ponder BAJ, Smith DP. RET alternative splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2. *Oncogene* 1997;14:763-71.
- 76 Durick K, Gill GN, Taylor SS. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2. *Mol Cell Biol* 1998;18:2298-308.
- 77 Califano D, Monaco C, De Vita G, D'Alessio A, Dathan NA, Possenti R, Vecchio G, Fusco A, Santoro M, de Franciscis V. Activated RET/PTC oncogene elicits immediate early and delayed response genes in PC12 cells. *Oncogene* 1995;11:107-12.
- 78 Worby CA, Vega QC, Zhao Y, Chao HHJ, Seasholtz AF, Dixon JE. Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. *J Biol Chem* 1996;271:23619-22.
- 79 van Weering DH, Medema JP, van Puijenbroek A, Burgering BM, Baas PD, Bos JL. Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. *Oncogene* 1995;11:2207-14.
- 80 van Weering DHJ, Bos JL. Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation. *J Biol Chem* 1997;272:249-54.
- 81 Califano D, Rizzo C, D'Alessio A, Colucci-D'Amato GL, Cali G, Cannada Bartoli P, Santelli G, Vecchio G, de Franciscis V. Signaling through Ras is essential for Ret oncogene-induced cell differentiation in PC12 cells. *J Biol Chem* 2000;275:19297-305.
- 82 Iwashita T, Asai N, Murakami H, Matsuyama M, Takahashi M. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. *Oncogene* 1996;12:481-7.
- 83 Colucci-D'Amato GL, D'Alessio A, Califano D, Cali G, Rizzo C, Nitsch L, Santelli G, de Franciscis V. Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK. *J Biol Chem* 2000;275:19306-14.
- 84 Soler RM, Dolcet X, Encinas M, Egea J, Bayascas JR, Comella JX. Receptors of the glial cell line-derived neurotrophic factor family of neurotrophic factors signal cell survival through the phosphatidylinositol 3-kinase pathway in spinal cord motoneurons. *J Neurosci* 1999;19:9160-9.
- 85 Murakami H, Iwashita T, Asai N, Iwata Y, Narumiya S, Takahashi M. Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130Cas mediated by Ret kinase. *Oncogene* 1999;18:1975-82.
- 86 Romano A, Wong WT, Santoro M, Wirth PJ, Thorgeirsson SS and DiFiore PP. The high transforming potency of erbB-2 and ret is associated with phosphorylation of paxillin and a 23 kDa protein. *Oncogene* 1994;9:2923-33.
- 87 King S, Smanik PA, Oglesbee MJ, Trosko JE, Mazzaferri EL, Jhiang SM. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes. *Endocrinology* 1996;137:1512-19.
- 88 Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-Kinase/AKT signaling pathway. *J Biol Chem* 2000;275:3568-76.
- 89 van Weering DH, de Rooij J, Marte B, Downward J, Bos JL, Burgering BM. Protein kinase B activation and lamellipodium formation are independent phosphoinositide 3-kinase-mediated events differentially regulated by endogenous Ras. *Mol Cell Biol* 1998;18:1802-11.
- 90 Marshall GM, Peaston AE, Hocker JE, Smith SA, Hansford LM, Tobias V, Norris MD, Haber M, Smith DP, Lorenzo MJ, Ponder BAJ, Hancock JF. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion *in vitro*, enhances metastatic behavior *in vivo* and activates Jun kinase. *Cancer Res* 1997;57:5399-405.
- 91 Santoro M, Wong WT, Aroca P, Santos E, Matoskova B, Grieco M, Fusco A, di Fiore PP. An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway. *Mol Cell Biol* 1994;14:663-75.
- 92 Asai N, Murakami H, Iwashita T, Takahashi M. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with Shc adaptor proteins. *J Biol Chem* 1996;271:17644-9.
- 93 Durick K, Yao VJ, Borrello MG, Bongarzone I, Pierotti MA, Taylor SS. Tyrosines outside the kinase core and dimerization domain are required for the mitogenic activity of RET/ptc2. *J Biol Chem* 1995;270:24642-5.
- 94 Ohiwa M, Murakami H, Iwashita T, Asai N, Iwata Y, Imai T, Funahashi H, Takagi H, Takahashi M. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations. *Biochem Biophys Res Commun* 1997;237:747-51.
- 95 Myers SM, Eng C, Ponder BAJ, Mulligan LM. Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C terminus for RET. *Oncogene* 1995;11:2039-45.
- 96 Tahira T, Ishizaka Y, Itoh F, Sugimura T, Nagao M. Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. *Oncogene* 1990;5:97-102.
- 97 Ishiguro Y, Iwashita T, Murakami H, Asai N, Iida K, Goto H, Hayakawa T, Takahashi M. The role of amino acids surrounding tyrosine 1062 in ret in specific binding of the Shc phosphotyrosine-binding domain. *Endocrinology* 1999;140:3992-8.
- 98 Rossel M, Pasini A, Chappuis S, Geneste O, Fournier L, Schuffenecker I, Takahashi M, van Grunsven LA, Urdiales JL, Rudkin BB, Lenoir GM, Billaud M. Distinct biological properties of two RET isoforms activated by MEN 2A/FMTC and MEN 2B mutations. *Oncogene* 1997;14:265-75.
- 99 Ivanchuk SM, Myers SM, Mulligan LM. Expression of RET 3' alternatively spliced transcripts during human kidney development. *Oncogene* 1998;16:991-6.
- 100 Eng C. RET proto-oncogene in the development of human cancer. *J Clin Oncol* 1999;17:380-93.
- 101 Lips CJM, Landsvater RM, Höppener JWM, Geerdink RA, Blijham G, Jansen-Schillhorn van Veen JM, van Gils APG, de Wit MJ, Zewald RA, Berends MJH, Beemer FA, Brouwers-Smalbraak J, Jansen RPM, Ploos van Amstel HK, van Vroonhoven TJMV, Vroom TM. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. *N Engl J Med* 1994;331:828-35.
- 102 Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, Nevell DF, Diamond T, Delbridge L, Clifton-Bligh P, Robinson BG. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN2A families. *Clin Endocrinol* 1995;44:213-20.
- 103 Offit K, Biesecker BB, Burt RW, Clayton EW, Garber JE, Kahn MJ. Statement of the American Society of Clinical Oncology - Genetic testing for cancer susceptibility. *J Clin Oncol* 1996;14:1730-6.
- 104 Telander RL, Zimmerman D, Sizemore GW, van Heerden JA, Grant CS. Medullary carcinoma in children. Results of early detection and surgery. *Arch Surg* 1989;124:841-3.
- 105 Jhiang S, Mazzaferri E. The ret/PTC oncogene in papillary thyroid carcinoma. *J Lab Clin Med* 1994;123:331-7.
- 106 Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D, Klugbauer S. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. *Clin Cancer Res* 2000;6:1093-103.
- 107 Passarge E. The genetics of Hirschsprung's disease. Evidence for heterogeneous etiology and a study of sixty-three families. *N Engl J Med* 1967;276:138-43.
- 108 Attié T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, Boutran L, Beldjord C, Nihoul-Fékété C, Munnich A, Ponder BAJ, Lyonnet S. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. *Hum Mol Genet* 1995;4:1381-6.
- 109 Iwashita T, Murakami H, Asai N, Takahashi M. Mechanisms of Ret dysfunction by Hirschsprung mutations affecting its extracellular domain. *Hum Mol Genet* 1996;5:1577-80.
- 110 Carlomagno F, De Vita G, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, Kraus MH, Di Fiore PP, Fusco A, Santoro M. Molecular heterogeneity of RET loss of function in Hirschsprung's disease. *EMBO J* 1996;15:2717-25.
- 111 Sancandi M, Ceccherini I, Costa M, Fava M, Chen B, Wu Y, Hofstra R, Laurie T, Griffiths M, Burge D, Tam PK. Incidence of RET mutations in patients with Hirschsprung's disease. *J Pediatr Surg* 2000;35:139-42.
- 112 Svensson PJ, Molander ML, Eng C, Anvret M, Nordenskjöld A. Low frequency of RET mutations in Hirschsprung disease in Sweden. *Clin Genet* 1998;54:39-44.
- 113 Angrist M, Bolk S, Halushka M, Lapchak PA, Chakravarti A. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. *Nat Genet* 1996;14:341-3.
- 114 Ivanchuk SM, Myers SM, Eng C, Mulligan LM. De novo mutation of GDNF, ligand of the RET/GDNFR- α receptor complex in Hirschsprung disease. *Hum Mol Genet* 1996;5:2023-6.
- 115 Salomon R, Attié T, Pelet A, Bidaud C, Eng C, Amiel J, Sarnacki S, Goulet O, Ricour C, Nihoul-Fékété C, Munnich A, Lyonnet S. Germline mutations of the RET ligand, GDNF, are not sufficient to cause Hirschsprung disease. *Nat Genet* 1996;14:345-7.
- 116 Doray B, Salomon R, Amiel J, Pelet A, Touraine R, Billaud M, Attié T, Bachy B, Munnich A, Lyonnet S. Mutation of the RET ligand, neurturin, supports multi-genetic inheritance in Hirschsprung disease. *Hum Mol Genet* 1998;7:1449-52.
- 117 Angrist M, Jing S, Bolk S, Bentley K, Nallasamy S, Halushka M, Fox GM, Chakravarti A. Human *GFR α 1*: cloning, mapping, genomic structure and evaluation as a candidate gene for Hirschsprung disease susceptibility. *Genomics* 1998;48:354-62.
- 118 Myers SM, Salomon R, Goessling A, Pelet A, Eng C, von Deimling A, Lyonnet S, Mulligan LM. Investigation of germline *GFR α -1* mutations in Hirschsprung disease. *J Med Genet* 1999;36:217-21.
- 119 Onochie CI, Kornig LM, Myers SM, VanHorne JB, Michaud D, Mulligan LM. Characterization of *GFR α -3* and investigation of the gene in Hirschsprung disease. *J Med Genet* 2000;37:674-9.

- 120 Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, Eng C. Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. *J Med Genet* 1999;**36**:771-4.
- 121 Fitze G, Schreiber M, Kuhlisch E, Schackert HK, Roesner D. Association of RET protooncogene codon 45 polymorphism with Hirschsprung disease. *Am J Hum Genet* 1999;**65**:1469-73.
- 122 Auricchio A, Griseri P, Carpentieri ML, Betsos N, Staiano A, Tozzi A, Priolo M, Thompson H, Bocciardi R, Romeo G, Ballabio A, Ceccherini I. Double heterozygosity for a RET substitution interfering with splicing and an EDNRB missense mutation in Hirschsprung disease. *Am J Hum Genet* 1999;**64**:1216-21.
- 123 Svensson PJ, Anvret M, Molander ML, Nordenskjold A. Phenotypic variation in a family with mutations in two Hirschsprung-related genes (RET and endothelin receptor B). *Hum Genet* 1998;**103**:145-8.
- 124 Bolk S, Pelet A, Hofstra RM, Angrist M, Salomon R, Croaker D, Buys CH, Lyonnet S, Chakravarti A. A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. *Proc Natl Acad Sci USA* 2000;**97**:268-73.
- 125 Mulligan LM, Eng C, Attié T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, Venter DJ, Munnich A, Ponder BAJ. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. *Hum Mol Genet* 1994;**3**:2163-7.
- 126 Borst MJ, VanCamp JM, Peacock ML, Decker RA. Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. *Surgery* 1995;**117**:386-91.
- 127 Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J, Horellou P. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. *Proc Natl Acad Sci USA* 1997;**94**:8818-23.
- 128 Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA. Functional recovery in parkinsonian monkeys treated with GDNF. *Nature* 1996;**380**:252-5.
- 129 Rosenblad C, Gronborg M, Hansen C, Blom N, Meyer M, Johansen J, Dago L, Kirik D, Patel UA, Lundberg C, Trono D, Bjorklund A, Johansen TE. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. *Mol Cell Neurosci* 2000;**15**:199-214.